Compare MCD & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCD | TMO |
|---|---|---|
| Founded | 1940 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Industrial Machinery/Components |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.9B | 216.4B |
| IPO Year | N/A | N/A |
| Metric | MCD | TMO |
|---|---|---|
| Price | $309.65 | $577.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 20 |
| Target Price | $326.35 | ★ $630.42 |
| AVG Volume (30 Days) | ★ 3.3M | 1.6M |
| Earning Date | 11-05-2025 | 01-29-2026 |
| Dividend Yield | ★ 2.40% | 0.30% |
| EPS Growth | 2.90 | ★ 8.54 |
| EPS | 11.72 | ★ 17.32 |
| Revenue | $26,264,000,000.00 | ★ $43,736,000,000.00 |
| Revenue This Year | $3.93 | $4.33 |
| Revenue Next Year | $5.61 | $4.94 |
| P/E Ratio | ★ $26.43 | $33.43 |
| Revenue Growth | 1.25 | ★ 3.22 |
| 52 Week Low | $276.53 | $385.46 |
| 52 Week High | $326.32 | $610.97 |
| Indicator | MCD | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 53.90 | 53.59 |
| Support Level | $306.01 | $561.91 |
| Resistance Level | $313.75 | $575.25 |
| Average True Range (ATR) | 4.77 | 11.79 |
| MACD | 0.22 | -3.00 |
| Stochastic Oscillator | 70.80 | 41.03 |
McDonald's is the largest restaurant owner-operator in the world, with 2024 system sales of $131 billion across more than 43,000 stores and 115 markets. McDonald's pioneered the franchise model, building its footprint through partnerships with independent restaurant franchisees and master franchise partners around the globe. The firm earns roughly 60% of its revenue from franchise royalty fees and lease payments, with most of the remainder coming from company-operated stores across its three core segments: the United States, internationally operated markets, and international developmental/licensed markets.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).